544417-40-5

Usage

Uses

Used in Cardiology:
Capadenoson is used as a diagnostic agent for coronary artery disease. It is used to induce hyperemic response and widen the coronary arteries, allowing for the assessment of blood flow and the identification of any blockages or narrowing in the coronary arteries.
Used in Cardiac Stress Testing:
Capadenoson is used as a pharmacological stress agent in cardiac stress testing. It helps to increase the heart rate and blood flow to the heart muscle, allowing for the evaluation of the heart's function under stress conditions.
Used in Myocardial Perfusion Imaging:
Capadenoson is used as a contrast agent in myocardial perfusion imaging. It enhances the visualization of blood flow to the heart muscle, aiding in the detection of areas with reduced blood flow, which may indicate the presence of coronary artery disease.
Used in Pharmaceutical Industry:
Capadenoson is used as a research and development compound in the pharmaceutical industry. Its selective activation of the A2A adenosine receptor makes it a valuable tool for studying the role of adenosine receptors in cardiovascular diseases and for developing new therapeutic agents targeting these receptors.

Upstream product

• 22042-73-5 4-(2-hydroxy-ethoxy)-benzaldehyde 
• 17969-22-1 4-chloromethyl-2-(4-chloro-phenyl)-thiazole 
• 112906-84-0 2-[4-(2-hydroxyethoxy)benzylidene]malononitrile 
• 7357-70-2 Cyanothioacetamide 
• 2521-24-6 4-chlorothiobenzamide 
• 544417-72-3 2-amino-4-[4-(2-hydroxyethoxy)phenyl]-6-sulfanylpyridine-3,5-dicarbonitrile 

Downstream Products

• 1110660-72-4 2-{4-[2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}thio)-3,5-dicyanopyridin-4-yl]phenoxy}ethyl β-alanyl-L-valinate hydrochloride 
• 1110660-63-3 (2S)-5-(2-{4-[2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}thio)-3,5-dicyanopyridin-4-yl]phenoxy}ethoxy)-2-[(3-carboxypropanoy l)amino]-5-oxopentanoic acid 
• 1110660-30-4 2-{4-[2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}thio)-3,5-dicyanopyridin-4-yl]phenoxy}ethyl L-valinate trifluoroacetate 
• 1110660-33-7 2-{4-[2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}thio)-3,5-dicyanopyridin-4-yl]phenoxy}ethyl L-alaninate trifluoroacetate 
• 1110660-44-0 5-(2-{4-[2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}thio)-3,5-dicyanopyridin-4-yl]phenoxy}ethyl) 1-tert-butyl L-glutamate 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF 2-{4-[2-({[2-(4-CHLOROPHENYL)-1,3-THIAZOL-4-YL]METHYL}SULFANYL)-3,5-DICYAN0-6-(PYRROLIDIN-1-YL)PYRIDIN-4-YL]PHENOXY}ETHYL-L-ALANYL-L-ALANINATE MONOHYDROCHLORIDE

The present application relates to a novel and improved process for preparing the compound 2-{4-[2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulphanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl]phenoxy}ethyl-L-alanyl L-alaninate monohydrochloride of the formula (I) to novel precursors for its preparation, and to the preparation and use of crystal modification I of 2-{4-[2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulphanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl]phenoxy}-ethyl-L-alanyl L-alaninate monohydrochloride of the formula (I).

Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A1 Receptor Agonist for the Chronic Treatment of Heart Diseases

Adenosine is known to be released under a variety of physiological and pathophysiological conditions to facilitate the protection and regeneration of injured ischemic tissues. The activation of myocardial adenosine A1 receptors (A1Rs) has been shown to inhibit myocardial pathologies associated with ischemia and reperfusion injury, suggesting several options for new cardiovascular therapies. When full A1R agonists are used, the desired protective and regenerative cardiovascular effects are usually overshadowed by unintended pharmacological effects such as induction of bradycardia, atrioventricular (AV) blocks, and sedation. These unwanted effects can be overcome by using partial A1R agonists. Starting from previously reported capadenoson we evaluated options to tailor A1R agonists to a specific partiality range, thereby optimizing the therapeutic window. This led to the identification of the potent and selective agonist neladenoson, which shows the desired partial response on the A1R, resulting in cardioprotection without sedative effects or cardiac AV blocks. To circumvent solubility and formulation issues for neladenoson, a prodrug approach was pursued. The dipeptide ester neladenoson bialanate hydrochloride showed significantly improved solubility and exposure after oral administration. Neladenoson bialanate hydrochloride is currently being evaluated in clinical trials for the treatment of heart failure.

SUBSTITUTED AZABICYCLIC COMPOUNDS AND THE USE THEREOF

The present application relates to novel substituted pyrrolopyridine, pyrazolopyridine and isoxazolopyridine derivatives, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, preferably for the treatment and/or prevention of cardiovascular disorders.

ALKYLAMINO-SUBSTITUTED DICYANOPYRIDINES AND THEIR AMINO ACID ESTER PRODRUGS

The present application relates to novel 6-alkylamino-substituted dicyanopyridines, to their amino acid ester prodrugs, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular disorders.

USE OF ADENOSINE A1 RECEPTOR AGONISTS FOR THE PROTECTION OF RENAL CELLS AGAINST TOXIC EFFECTS CAUSED BY AMINOGLYCOSIDES DURING TREATMENT OF INFECTIOUS DISEASES

The present invention refers to the use of adenosine Al receptor agonists for the protection of renal cells against toxic effects caused by aminoglycosides during treatment of infectious diseases in human.